Literature DB >> 11032398

Interaction of retinoic acid and interferon in renal cancer cell lines.

D M Nanus1, Y Geng, R Shen, H K Lai, S R Pfeffer, L M Pfeffer.   

Abstract

Retinoic acid (RA) can potentiate the antitumor effect of interferons (IFN) in a variety of tumor types, including renal cell carcinoma (RCC). The mechanisms by which RA and IFN increase the antitumor effects in RCC are unknown. We used growth assays and mobility shift assays to examine the effects of combining 13-cis-retinoic acid (CRA) and IFN-alpha (plus IFN-gamma) on proliferation and on the expression of the IFN-specific transcription factor IFN-stimulated gene factor 3 (ISGF3) in RCC cell lines. Combining CRA and IFN-alpha resulted in a significant increase in growth inhibition in four cell lines compared with IFN-alpha or CRA alone. Binding of nuclear extracts from RCC cells to an IFN-stimulated response element (ISRE) oligonucleotide probe following incubation with IFN-alpha was not increased by CRA but was significantly increased by pretreatment by IFN-gamma in a time-dependent fashion. Proliferation assays showed that sequential addition of IFN-gamma and IFN-alpha significantly increased growth inhibition. IFN-alpha but not IFN-gamma or CRA increased the cellular levels Stat2 and p48 but not Statl. IFN-gamma pretreatment enhanced the upregulation of p48 levels by IFN-alpha. Combining RA and IFN results in additive growth inhibition on RCC cell lines. This increase in growth inhibition is not mediated by increased ISGF3 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032398     DOI: 10.1089/10799900050151058

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  3 in total

1.  Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.

Authors:  Isabelle Renard; Delia Mezzanzanica; Silvana Canevari; Silvano Ferrini; Jacques Boniver; Philippe Delvenne; Nathalie Jacobs
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Phase II trial of fenretinide in advanced renal carcinoma.

Authors:  Ulka Vaishampayan; Lance K Heilbrun; Ralph E Parchment; Vikash Jain; James Zwiebel; Ramesh R Boinpally; Patricia LoRusso; Maha Hussain
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

3.  Understanding the Action of RARγ Agonists on Human Osteochondroma Explants.

Authors:  Sonia A Garcia; Hongying Tian; Yuka Imamura-Kawasawa; Aidan Fisher; Ashley Cellini; Casey Codd; John E Herzenberg; Joshua M Abzug; Vincent Ng; Masahiro Iwamoto; Motomi Enomoto-Iwamoto
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.